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harmaceuticals make a major to 
contribution to health. However, 
as noted by Ess et al., in Europe 
over the last 20 years, expenditure on 
pharmaceuticals has grown faster than 
the gross national product, and Wagner 
and McCarthy described the problem 
in low-income countries  where “the 
vast majority are unwilling to pay for 
effective drugs simply because they 
are unable to pay” [1,2]. Up until the 
1990s, studies examining drug prices 
were few and far between, and in 
developing countries were nonexistent. 
Measuring comparative prices of 
medicines was seen as complex, and 
rightly so—many methodological 
challenges face such studies (Box 1) 
[3,4]. 
Work by Health Action 
International (HAI) in the late 1990s 
started to address these questions. 
In 1998, a study reported by HAI [5] 
described the variability of the price 
of ranitidine, sampled in multiple 
countries. In India at that time, one 
hundred 150 mg tablets could be 
bought for USD 2, whereas in South 
Africa, the price was USD 150. The 
key message from this study was that 
prices of common medicines vary 
enormously between countries and 
often within countries as well. If 
affordability is a barrier to availability 
of medicines, this was one of the ﬁ  rst 
studies to try to quantify the gap.
A New Study on Drug Pricing
In a new study published in PLoS 
Medicine, Babar et al. [6] report the 
results of a survey of drug prices and 
availability in Malaysia. This is one of 
many surveys that have been carried 
out, using a standard methodology for 
pricing surveys that has been developed 
by HAI in collaboration with the World 
Health Organisation since 1998. This 
standard method encourages systematic 
data collection, reporting, and analysis 
of prices of a “basket of medicines” to 
enable comparison within and across 
countries with the aim of informing 
pharmaceutical policy development. 
The method has been ﬁ  eld tested, 
validated, and used in nearly 50 surveys 
in different countries, the results 
of which are all publicly available 
on the HAI Web site (http:⁄⁄www.
haiweb.org/medicineprices). Having 
an internationally agreed method 
for surveys is an important step in 
improving the acceptance of the 
results; medicine prices are always a 
politically sensitive subject.
In the Malaysian context, which 
is a “free market” for medicines, 
the authors documented signiﬁ  cant 
variation in the prices of the standard 
sample of medicines. In the private 
sector, prices were substantially higher 
than the international reference price. 
Where a doctor was allowed to dispense 
medicines as well as prescribe them, 
there was a similar discrepancy in 
price, with very high markups being 
charged. Markups at other points in 
the pharmaceutical supply chain were 
also found to be high, contributing 
to high drug prices overall. For a 
selected subsample of medicines, 
detailed data were collected on all 
components of the ﬁ  nal prices: the 
markups added along the supply chain 
from the manufacturer to the point 
of sale to the patient. Based on the 
index measure of affordability—a day’s 
wages for a government worker—the 
authors suggest that even in the public 
sector, many essential medicines 
would be unaffordable. The overall 
assessment was that compared to 
international reference standards 
and other countries at the same level 
of development, Malaysian medicine 
prices were very high.
Limitations of the Study
The limitations of this study are those 
of most one-off cross-sectional surveys: 
How representative are the results for 
the pharmacies and facilities sampled 
overall? In a country of 20 million 
people with hundreds of hospitals 
and pharmacies, is it sufﬁ  cient to 
draw general/national conclusions 
from a sample of 20 public hospitals, 
32 private sector pharmacies, and 20 
dispensing doctors? This is clearly 
an important limitation, and ideally 
repeating the survey using a larger 
sample, or with repeated measures over 
time, would provide a more robust 
picture. However, in the absence of 
automated systems for recording the 
dispensing, prescribing and cost of 
medicines, data collection of medicine 
prices is labour intensive, and it is 
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Box 1. Methodological 
Challenges in Studying 
Comparative Drug Prices
•  What products do you sample? 
•  Where do you sample? 
•  If you choose to sample retail suppliers, 
in what area do you sample them? 
•  How many samples from each source? 
•  Brand or generic medicines? 
•  What if there are multiple generic 
versions of the same medicine? 
•  How do you measure the components 
that contribute to the ﬁ  nal price paid 
by the patient/consumer?
•  How do you compare across countries, 
given very different systems of supply 
and pricing structures?PLoS Medicine  |  www.plosmedicine.org 0412
therefore necessary to balance the ideal 
with the possible. Having some initial 
results provides a starting point for 
untangling the problem of high drug 
prices in Malaysia.
Policy Implications
The challenge now for the authors, and 
also for the HAI project overall, is to 
answer the “so-what” question. Prices of 
medicines in Malaysia may be high, but 
are these prices really affecting access to 
medicines (hard to measure) or health 
outcomes (even harder to measure)? 
Should there be wholesale policy change 
from a “free market” to control of 
medicine prices? If so, should all points 
in the supply chain be regulated—that 
is, from manufacturer to dispensing—or 
just some? If so, how? What policies 
are possible, and what impact would 
they have? South Africa has taken 
the step of introducing controls on 
pharmacist dispensing fees [7], but 
could have also opted to regulate other 
parts of the supply chain—what would 
be the impact? In a low- or middle-
income country, how do you decide 
on the tradeoff between regulating 
prices and supporting the local 
pharmaceutical industry, which might 
be your main source of cheap(er), but 
good quality products? A systematic 
review by Aaserud et al. [8] published 
last year summarized studies of some 
pricing policies that are widely used in 
developed countries, and concluded 
that there is very little information to 
assess beneﬁ  ts and harms of particular 
policy options, in terms of impact on 
prices, affordability, or health comes. 
But this review did not ﬁ  nd any studies 
from developing countries that could 
inform decision-making, and most of 
the policies were variations on reference 
pricing approaches. 
Next Steps
As noted on the HAI Web site, 
“Reliable data is the ﬁ  rst step to 
exploring policy options and taking 
action.” There are many question to 
answer. For each country that has 
done the survey, like the Malaysian 
study, the ﬁ  rst question is whether 
this a true picture of the situation 
and whether it remains so over time. 
The study samples only a limited 
number of medicines—what about 
other important groups (such as 
children and the terminally ill)? But 
most importantly, once the data are 
collected, what are the policy options 
for a country and what impact will they 
have? If there is to be any chance of 
evidence informing policy decisions 
in this challenging ﬁ  eld, then the 
transparent process encouraged and 
developed by HAI must continue—
prices cannot be the subject of closed-
door negotiations and the factors 
that contribute to pricing should be 
detailed so that those who pay know 
what they are getting for their money.  
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